SEC Form 4 · accession 0001209191-19-010954
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Douglas Wilson
Officer — Chief Financial Officer
Period of report
Feb 15, 2019
Accepted (ET)
Feb 19, 2019 · 1:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF2 | Feb 15, 2019 | C | 4,000 | — | A | 4,000 | D | |
| Class A common stock | Feb 15, 2019 | S | 4,000 | $85.44 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3,F2 | $11.00 | Feb 15, 2019 | M | 4,000 | D | — | May 25, 2026 | Class B common stock | 4,000 | 93,881 | D |
| Class B common stockF2 | — | Feb 15, 2019 | M | 4,000 | A | — | — | Class A common stock | 4,000 | 47,646 | D |
| Class B common stockF2 | — | Feb 15, 2019 | C | 4,000 | D | — | — | Class A common stock | 4,000 | 43,646 | D |
Explanation of responses
- F1The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2018.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- F3The options, representing a right to purchase a total of 101,881 shares, vest in twenty equal quarterly installments beginning on August 25, 2016.